Background {#Sec1}
==========

Enteric fever is an infection caused by *Salmonella enterica* serotype *Typhi* and *Paratyphi* \[[@CR1]\]. It has been estimated that there are worldwide, approximately 22 millions typhoid cases and 200,000 deaths per year \[[@CR2]\]. *Salmonella enterica* serovar *Paratyphi A* causes additional 5·4 millions illnesses \[[@CR2]\]. Enteric fever, is a serious public health problem in Nepal and is attributed to fecal contamination of foods and drinking water \[[@CR3]\].

Since 1989, multidrug resistant strains of *Salmonella*, those are no longer susceptible to the first line antibiotics have emerged \[[@CR4]\]. Multidrug resistant *Salmonella enterica* strains (resistant to chloramphenicol, ampicillin, cotrimoxazole) are common in Asia \[[@CR5]\]. During the past two decades, more than 80 % of the known multidrug resistant strains of *Salmonella* have been reported from Pakistan, Iran, Nepal, Bangladesh and India \[[@CR6], [@CR7]\]. And the fluoroquinolones have been suggested as the drugs of choice for the treatment of the enteric fever caused by species of *Salmonella* resistant to first line antibiotics \[[@CR8]\].

Over the last decade there have been several enteric fever epidemics in Nepal \[[@CR9], [@CR10]\] with changing antibiotic resistance patterns \[[@CR11]\]. The multidrug resistant *S. Typhi* in Nepal was first reported in 1991 \[[@CR12]\]. Subsequently, with the introduction of fluoroquinolones for the treatment of enteric fever, nalidixic acid-resistant strains associated with reduced susceptibility to fluoroquinolones have been increasingly reported from Nepal \[[@CR10]\]. And the use of third generation cephalosporins and azithromycin as treatment options for enteric fever has increased \[[@CR13]\]. There have been reports of occasional isolation of the highly fluoroquinolone resistant and third generation cephalosporin resistant strains of *S. Typhi* and *S. Paratyphi A* from Nepal \[[@CR14], [@CR15]\]. And recently the re-emergence of the conventional first-line drugs susceptible strains of *Salmonella* spp. in Nepal has been reported (Susceptibility of *Salmonella Typhi* to chloramphenicol and cotrimoxazole was 100 % and that to ampicillin was 98.2 %. Similarly, 100 % of *S. Paratyphi A* strains were sensitive to cotrimoxazole and ampicillin with 96.7 % of the isolates being sensitive to chloramphenicol) \[[@CR13]\]. In the present situation, when the treatment options for enteric fever are decreasing, the re-emergence of strains of the *Salmonella* susceptible to ampicillin, chloramphenicol, and cotrimoxazole should be evaluated to find out their therapeutic importance \[[@CR13]\]. For timely proper management of the enteric fever the knowledge of the prevalence of the different serovars of *Salmonella* and their antimicrobial susceptibility patterns is of utmost importance \[[@CR13]\].

In this study we studied the antimicrobial susceptibility patterns of *Salmonella Typhi* and *Salmonella Paratyphi A* isolated from the blood samples of the patients suspected of suffering from enteric fever toward different commonly used antibiotics. Reduced susceptibility of nalidixic acid-resistant strains to fluoroquinolones was also evaluated.

Methods {#Sec2}
=======

A cross-sectional study was carried out from November 2012 to May 2013, at a tertiary care hospital in Kathmandu, Nepal. A total of 620 patients clinically suspected of suffering from enteric fever, were included in the study. Patients who had already received antibiotics were not included in the study. Blood samples were collected aseptically by vein puncture and inoculated immediately into brain heart infusion broth. The amount of blood collected from adults was 5 ml and that from children was 2 ml. The ratio of amount of blood to that of brain heart infusion broth was maintained to be 1:10. After incubation, at 37 °C for 24, 48 and 72 hrs subcultures were done on MacConkey agar and blood agar and were observed for bacterial growth after 24 hrs of aerobic incubation at 37 °C. Isolates were identified by biotyping (colony morphology, staining reaction and biochemical characteristics) and serotyping using specific antisera (Denka Seiken Co. Ltd, Tokyo, Japan) \[[@CR16]\]. Samples were considered negative for *Salmonella*, if no growth was observed on subculture after 7 days of aerobic incubation at 37 °C. Antimicrobial susceptibility testing for *Salmonella* serovars was performed by Kirby Bauer disc diffusion technique following CLSI guidelines \[[@CR17]\]. The antibiotic discs used were, ampicillin (30 μg), nalidixic acid (30 μg), ofloxacin (5 μg), ciprofloxacin (5 μg), chloramphenicol (30 μg), ceftriaxone (30 μg), cotrimoxazole (1.25 μg), cefotaxime (30 μg), azithromycin (15 μg), and cefixime (30 μg). Minimum inhibitory concentrations of nalidixic acid, ofloxacin and ciprofloxacin were determined by agar dilution method as suggested by Andrews \[[@CR18]\] following CLSI guidelines \[[@CR17]\]. *Escherichia coli* ATCC 25922 was used for quality control. Statistical analysis was performed by using SPSS 19.0.

Results {#Sec3}
=======

Out of 620 blood samples, 83 (13.38 %) samples were culture positive for *Salmonella* spp. Out of total 83 *Salmonella* spp. isolated, 48 (57.83 %) were *Salmonella Typhi* and 35 (42.26 %) were *Salmonella Paratyphi A*.

Antimicrobial susceptibility patterns of *Salmonella* spp. toward different commonly used antibiotics {#Sec4}
-----------------------------------------------------------------------------------------------------

Among the antibiotics used for susceptibility testing of the isolates, all the isolates were found to be susceptible to cefixime, ceftriaxone, cefotaxime and azithromycin. Similarly, 98.8 % of the *Salmonella* spp. were susceptible to chloramphenicol and co-trimoxazole and about 97.6 % of the isolates were susceptible to ampicillin and ofloxacin. Only 16.9 % of the isolates were found to be susceptible to ciprofloxacin and nalidixic acid. 79.5 % of the isolates were intermediate sensitive to ciprofloxacin. Only one isolate was found to be multidrug resistant (showing resistance to ampicillin, chloramphenicol, cotrimoxazole and nalidixic acid) (Table [1](#Tab1){ref-type="table"}).Table 1Antimicrobial susceptibility patterns of *Salmonella* spp. toward different commonly used antibioticsAntibioticsNumberResistance (%)Intermediate (%)Sensitive (%)Ampicillin832.4097.6Ceftriaxone8300100Cefotaxime8300100Cefixime8300100Nalidixic acid8383.1016.9Ciprofloxacin833.679.516.9Ofloxacin8302.497.6Cotrimoxazole831.2098.8Azithromycin8300100Chloramphenicol831.2098.8

Minimum inhibitory concentrations of nalidixic acid, ciprofloxacin and ofloxacin for *Salmonella* isolates {#Sec5}
----------------------------------------------------------------------------------------------------------

About 24.1 % of the isolates had minimum inhibitory concentration of nalidixic acid (≥ 16 μg/ml) and that of ciprofloxacin (≥ 0.5 μg/ml) in resistant range. Similarly, 59 % of the isolates had minimum inhibitory concentration of nalidixic acid (≥ 16 μg/ml) in resistant range but that of ciprofloxacin (0.064 μg/ml to 0.5 μg/ml) in intermediate susceptible range. Again, 16.9 % of the isolates had minimum inhibitory concentration of nalidixic acid (≤ 16 μg/ml) and that of ciprofloxacin (≤ 0.064 μg/ml) in susceptible range (Table [2](#Tab2){ref-type="table"}). Likewise, 1.2 % of the isolates had minimum inhibitory concentration of ofloxacin (≥ 1 μg/ml) and that of nalidixic acid (≥ 16 μg/ml) in resistant range. Approximately, 69.9 % of the isolates had minimum inhibitory concentration of ofloxacin (≤ 0.125 μg/ml) in susceptible range while that of nalidixic acid (≥ 16 μg/ml) in resistant range. Around, 12 % of the isolates had minimum inhibitory concentration of ofloxacin (0.125 μg/ml to1 μg/ml) in intermediate susceptible range but that of nalidixic acid (≥ 16 μg/ml) in resistant range. Finally, 16.9 % of the isolates had minimum inhibitory concentration of nalidixic acid (≤ 16 μg/ml) and that of ofloxacin (≤ 0.125 μg/ml) in susceptible range (Table [3](#Tab3){ref-type="table"}).Table 2Susceptibility of the *Salmonella* spp. toward nalidixic acid and ciprofloxacin on the basis of minimum inhibitory concentrationNalidixic acid and ciprofloxacin resistant (%)Nalidixic acid resistant and ciprofloxacin intermediate (%)Nalidixic acid and ciprofloxacin sensitive (%)24.1 %59 %16.9 %Table 3Susceptibility of the *Salmonella* spp. toward nalidixic acid and ofloxacin on the basis of minimum inhibitory concentrationNalidixic acid and ofloxacin resistant (%)Nalidixic acid resistant and ofloxacin sensitive (%)Nalidixic acid resistant and ofloxacin intermediate (%)Nalidixic acid and ofloxacin sensitive (%)1.2 %69.9 %12 %16.9 %

Discussion {#Sec6}
==========

Similar rate of culture positivity as in our study (13.38 %) was also found in another study conducted in Nepal (15.6 %) \[[@CR19]\]. Typhoid and paratyphoid, collectively known as 'enteric fever', remains as one of the commonest causes of the fever in most parts of under developed world including Nepal \[[@CR20]\]. The enteric fever is endemic in most of the urban areas of Nepal including Kathmandu, mainly due to cross contamination of the drinking water with sewage \[[@CR10], [@CR21]\]. As in our study higher prevalence of *S*. Typhi (57.83 %) in comparison to *S*. Paratyphi A (42.26 %) (*p* \< 0.05) was also reported in another study conducted in Nepal {*S*. Typhi (64.1 %) and *S*. Paratyphi A (35.9 %)} \[[@CR22]\]. In both studies *S*. Paratyphi B and C were not isolated.

In present study, the rate of nalidixic acid resistance, which is a phenotypic marker for reduced susceptibility to fluoroquinolones \[[@CR23]\]; was observed high (83.1 %). Similar rates of nalidixic acid resistance were also reported in other studies conducted in India (86.27 %) \[[@CR24]\] and Nepal (91.1 % for *S*. Typhi and 90.0 % for *S*. Paratyphi A) \[[@CR13]\]. In contrast to nalidixic acid resistance, in present study re-emergence of susceptibility (98.8 % susceptibility to chloramphenicol and co-trimoxazole and 97.6 % susceptibility to ampicillin) to conventional first line drugs used for treatment of enteric fever was observed. Similar types of findings were also observed by Garg et al. (1.96, 15.6, and 6.8 % resistance to chloramphenicol, ampicillin, and co-trimoxazole respectively) \[[@CR24]\], Acharya et al. (95.12 % susceptibility to all first line antibiotics) \[[@CR25]\], and Acharya et al. (more than 95.5 % susceptibility to all first line antibiotics) \[[@CR26]\]. The increased use of the fluoroquinolones and the discontinuation in the use of the conventional first line antibiotics (ampicillin, chloramphenicol, and co-trimoxazole) for treatment of the enteric fever for long periods of time may be the reason behind the reduced susceptibility of *Salmonella* strains to fluoroquinolones and re-emergence of first line antibiotics susceptible *S. Typhi* and *S. Paratyphi A* isolates. Further, the loss of the plasmids responsible for resistance to first line drugs may be the reason for the re-emergence of the susceptible strains \[[@CR13]\].

Among fluoroquinolones higher percentage of susceptibility was shown toward ofloxacin (97.6 %) followed by ciprofloxacin (16.9 %). But we do not recommend to use ofloxacin for the treatment of enteric fever in our setting, as high rate of nalidixic acid-resistance among *Salmonella* isolates was noted in our study, which indicates the high probability of developing ofloxacin resistance in near future, if the drug is used haphazardly. In Nepal, all the *S. Typhi* and *S. Paratyphi A* isolates were reported as susceptible until 1998 but during 1999 to 2003 ciprofloxacin resistance increased to 5 % in the *S*. Typhi and 13 % in S. Paratyphi A \[[@CR9]\].

In contrast to our study, 100 % susceptibility of *Salmonella Typhi* and 96.7 % susceptibility of *Salmonella Paratyphi A* to ciprofloxacin were observed in a study by Chand et al. \[[@CR13]\]. The increased haphazard use of ciprofloxacin as empirical therapy for treatment of enteric fever in recent years may have contributed to this discrepancy. Among cephalosporins and macrolides all the isolates were susceptible to cefotaxime, cefixime, ceftriaxone and azithromycin. But among the cephalosporins, cefixime may attract more attention as drug of choice as it can be used orally \[[@CR27]\]. Only one isolate was found to be multidrug resistant in present study and the finding correlated with the previous study that reported the decreasing trend in multidrug resistant isolates during the period of 2000--2004 \[[@CR28]\]. Due to irrational use of antibiotics, the rate of drug resistance among bacteria is increasing and the situation is worse in developing countries \[[@CR29], [@CR30]\]. So antibiotics should be used only on the basis of culture and sensitivity report.

Our findings will be helpful for the clinician to choose the appropriate empirical therapy for the treatment of enteric fever. Further it will also be helpful to make policy for empirical therapy for treatment of enteric fever.

Limitations of the study {#Sec7}
------------------------

Due to short duration of the time available for research and lack of resources we could not include more samples in the study. Further, due to lack of sophisticated laboratory and lack of fund we could not confirm our results with molecular techniques. Minimum inhibitory concentrations of all the antibiotics used in antimicrobial susceptibility testing could not be determined. This is a study conducted in only one hospital, so multi-centered study covering wide geographical area would have generated more significant result.

Conclusions {#Sec8}
===========

The present study revealed the increased rate of nalidixic acid resistant *Salmonella* spp. associated with reduced susceptibility to fluoroquinolones in contrast to increased susceptibility of the strains to conventional first-line drugs ampicillin, chloramphenicol, and cotrimoxazole in Kathmandu, Nepal. So, the conventional first-line drugs along with the third generation cephalosporins and azithromycin can be used as empiric therapy for treatment of enteric fever in our setting. Multi-centered studies covering wide geographical area and large population are required to generate more significant data regarding the susceptibility of the *Salmonella* spp. toward ampicillin, co-trimoxazole and chloramphenicol and to determine the possibility of using these drugs for empirical therapy for treatment of enteric fever.
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